BiotechTube

SDP-133 + Lumigan

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open Angle Glaucoma

Conditions

Open Angle Glaucoma, Ocular Hypertension

Trial Timeline

Jun 10, 2019 → Jul 8, 2019

NCT ID
NCT03927443

About SDP-133 + Lumigan

SDP-133 + Lumigan is a phase 3 stage product being developed by Sun Pharmaceutical for Open Angle Glaucoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03927443. Target conditions include Open Angle Glaucoma, Ocular Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03927443Phase 3Withdrawn

Competing Products

20 competing products in Open Angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Ilofotase alfa + PlaceboAM-PharmaPhase 2
44
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
77
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
Pirtobrutinib + PlaceboEli LillyPhase 1/2
41
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
44
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
MicafunginAstellas PharmaApproved
85
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
77
Placebo + LusutrombopagShionogiPhase 2
52
LusutrombopagShionogiPhase 2
52
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
52
E5501EisaiPhase 1
33
avatrombopagEisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
77
avatrombopag + PlaceboEisaiPhase 2
52
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
52

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85